Clinical remission in patients with severe eosinophilic asthma treated with benralizumab who were randomised to reduce their inhaled corticosteroid/formoterol dose: SHAMAL post-hoc analysis

被引:0
|
作者
Devouassoux, Gilles [1 ,2 ,3 ]
Jackson, David J. [4 ]
Kaessner, Frank F. [5 ]
Caruso, Cristiano [6 ]
Shavit, Anat [7 ]
Olinger, Lynda [8 ,9 ]
Menzies-Gow, Andrew [7 ]
机构
[1] Hop Croix Rousse, Serv Pneumol, Lyon, France
[2] Univ Claude Bernard Lyon 1, VIRPATH, Villeurbanne, France
[3] CRISALIS, F CRIN INSERM Network, Pavillon Ler, Toulouse, France
[4] Kings Coll London, Guys Hosp, Sch Immunol & Microbial Sci, London, England
[5] MECS GmbH, Ambulantes Zentrum Lungenkrankheiten & Schlafmed, Cottbus, Brandenburg, Germany
[6] Fdn Policlin Univ Agostino Gemelli IRCCS, UOSD DH Internal Med & Digest Dis, Rome, Italy
[7] AstraZeneca, BioPharmaceut Med Resp & Immunol, Cambridge, England
[8] Cytel Inc, Waltham, MA USA
[9] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol, Cambridge, England
关键词
D O I
10.1183/13993003.congress-2024.PA1194
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
引用
收藏
页数:3
相关论文
共 46 条
  • [1] Effect of baseline long- acting muscarinic antagonist use on inhaled corticosteroid/ formoterol dose reduction in patients with severe eosinophilic asthma treated with benralizumab: SHAMAL post-hoc analysis
    Korn, S.
    Jandl, M.
    Humbert, M.
    Menzies-Gow, A.
    Shavit, A.
    Olinger, L.
    Jackson, D. J.
    ALLERGOLOGIE, 2024, 47 (09)
  • [2] Baseline characteristics of patients with severe eosinophilic asthma treated with benralizumab who reduced to anti-inflammatory reliever only vs high-, medium- or low- dose inhaled corticosteroid/formoterol: SHAMAL post-hoc analysis
    Kent, Brian
    Milger-Kneidinger, Katrin
    Heaney, Liam G.
    Menzies-Gow, Andrew
    Shavit, Anat
    Olinger, Lynda
    Jackson, David J.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [3] Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study
    Papaioannou, Andriana I.
    Kallieri, Maria
    Zervas, Eleftherios
    Fouka, Evangelia
    Porpodis, Konstantinos
    Mitrova, Marija Hadji
    Tzortzaki, Eleni
    Makris, Michael
    Ntakoula, Maria
    Lyberopoulos, Panagiotis
    Dimakou, Katerina
    Koukidou, Sofia
    Ampelioti, Sevasti
    Papaporfyriou, Anastasia
    Katsoulis, Konstantinos
    Kipourou, Maria
    Rovina, Nikoletta
    Antoniou, Katerina
    Vittorakis, Stylianos
    Bakakos, Petros
    Steiropoulos, Paschalis
    Markopoulou, Katerina
    Avarlis, Panteleimon
    Papanikolaou, Ilias C.
    Markatos, Miltiadis
    Gaki, Eleni
    Samitas, Konstantinos
    Glynos, Konstantinos
    Papiris, Spyros A.
    Papakosta, Despoina
    Tzanakis, Nikolaos
    Gaga, Mina
    Kostikas, Konstantinos
    Loukides, Stelios
    ALLERGY AND ASTHMA PROCEEDINGS, 2025, 46 (01) : 45 - 51
  • [4] LONG-TERM REMISSION AND OUTCOMES IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA RECEIVING BENRALIZUMAB: MELTEMI POST-HOC ANALYSIS
    Bourdin, Arnaud
    Shavit, Anat
    Swisher, Sean
    Cohen, David
    Korn, Stephanie
    CHEST, 2024, 166 (04) : 57A - 57A
  • [5] Factors influencing lung function changes when inhaled corticosteroid/formoterol is reduced in patients with severe eosinophilic asthma treated with benralizumab
    Jackson, David
    Shavit, Anat
    Kaessner, Frank F.
    Menzies-Gow, Andrew
    Olinger, Lynda
    Di Marco, Fabiano
    Devouassoux, Gilles
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [6] Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab:a post-hoc analysis of the 2-year RELIght study
    Papaioannou, Andriana
    Kallieri, Maria
    Zervas, Eleftherios
    Fouka, Evangelia
    Porpodis, Konstaninos
    Hadjimitrova, Marija
    Tzortzaki, Eleni
    Makris, Michael
    Ntakoula, Maria
    Lyberopoulos, Panagiotis
    Dimakou, Katerina
    Koukidou, Sofia
    Ampelioti, Sevasti
    Papaporfyriou, Anastasia
    Katsoulis, Konstantinos
    Kipourou, Maria
    Rovina, Nikoletta
    Antoniou, Katerina
    Vittorakis, Stylianos
    Bakakos, Petros
    Steiropoulos, Paschalis
    Markopoulou, Katerina
    Avarlis, Panteleimon
    Papanikolaou, lias
    Markatos, Miltiadis
    Gaki, Eleni
    Samitas, Konstantinos
    Glynos, Konstantinos
    Papiris, Spyros
    Papakosta, Despoina
    Tzanakis, Nikolaos
    Gaga, Mina
    Kostikas, Konstantinos
    Loukides, Stelios
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [7] Late Breaking Abstract - SHAMAL: reduction of maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab: a randomised phase 4 study
    Jackson, David J.
    Heaney, Liam G.
    Humbert, Marc
    Kent, Brian D.
    Hiljemark, Lina
    Olinger, Lynda
    Cohen, David
    Menzies-Gow, Andrew
    Korn, Stephanie
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [8] Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
    Jackson, David J.
    Heaney, Liam G.
    Humbert, Marc
    Kent, Brian D.
    Shavit, Anat
    Hiljemark, Lina
    Olinger, Lynda
    Cohen, David
    Menzies-Gow, Andrew
    Korn, Stephanie
    LANCET, 2024, 403 (10423): : 271 - 281
  • [9] Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
    Menzies-Gow, Andrew
    Hoyte, Flavia L.
    Price, David B.
    Cohen, David
    Barker, Peter
    Kreindler, James
    Jison, Maria
    Brooks, Christopher L.
    Papeleu, Peggy
    Katial, Rohit
    ADVANCES IN THERAPY, 2022, 39 (05) : 2065 - 2084
  • [10] Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
    Andrew Menzies-Gow
    Flavia L. Hoyte
    David B. Price
    David Cohen
    Peter Barker
    James Kreindler
    Maria Jison
    Christopher L. Brooks
    Peggy Papeleu
    Rohit Katial
    Advances in Therapy, 2022, 39 : 2065 - 2084